Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

64.49 -0.84 (-1.29%)
Streaming Delayed Price Updated: 12:20 PM EDT, May 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Gilead Sciences

< Previous 1 2 3 4 5 6 7 8 9
...
30 31 Next >
Shhh! 3 Secret Biotech Stocks Flying Below Wall Street’s Radar
These biotech stocks seem to be rich with intriguing growth plays going for very reasonable multiples this May. 
Via InvestorPlace
Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week
With the earnings season now halfway through, the percentage of S&P 500 companies reporting positive earnings surprises and the magnitude of earnings surprises were above their 10-year averages. 
Via Benzinga
Topics Stocks
Exposures US Equities
Gilead Sciences Unusual Options Activity
Via Benzinga
3 Dividend Stocks to Buy at a 52-Week Low in April
Explore these three dividend stocks trading near their 52-week lows, presenting compelling opportunities for income-oriented investors. 
Via InvestorPlace
Gilead Sciences (GILD) Q1 2024 Earnings Call Transcript
GILD earnings call for the period ending March 31, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
GILD Stock Earnings: Gilead Sciences Beats EPS, Beats Revenue for Q1 2024
GILD stock results show that Gilead Sciences beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Will Gilead's Big Veklury Beat Offset A Cancer Drug Miss?
Gilead beat first-quarter calls, but it came on the back of Covid drug Veklury. 
Via Investor's Business Daily
Exposures COVID-19
The Analyst Verdict: Gilead Sciences In The Eyes Of 12 Experts
Via Benzinga
What the Options Market Tells Us About Gilead Sciences
Via Benzinga
If You Invested $100 In This Stock 20 Years Ago, You Would Have $900 Today
Via Benzinga
Stocks Drop, Tech Tumbles With Meta's Weak Outlook, Q1 Stagflation Fears; Gold Miners Advance: What's Driving Markets Thursday?
Wall Street suffers a double blow in Thursday’s session, as softer-than-expected revenue forecasts from Meta Platforms Inc. (NASDAQ:META) are being compounded by weaker-than-expected economic growth... 
Via Benzinga
Topics Economy
Exposures Interest Rates
Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks Delivering High-Dividend Yields
Via Benzinga
Why Is Penny Stock HOOKIPA Pharma Trading Higher On Wednesday?
HOOKIPA Pharma secures FDA clearance for its innovative HB-700 therapeutic vaccine targeting KRAS-mutated cancers. Learn about its broad impact on lung, colorectal, and pancreatic cancers, achieving... 
Via Benzinga
Exposures Product Safety
Why the dividend investor may take a look at NASDAQ:GILD.
Uncovering Dividend Opportunities with GILEAD SCIENCES INC (NASDAQ:GILD). 
Via Chartmill
If You Invested $100 In This Stock 20 Years Ago, You Would Have $1,000 Today
Via Benzinga
US Stocks Brace For Negative Start Amid Tech Earnings Disappointments, Caution Ahead Of Data: 'Worst Of This Two-Week Decline Is Behind Us,' Says Analyst
The back-and-forth motion in the market continues, with the index futures pointing to a lower opening on Thursday. Meta Platforms, Inc.’s (NASDAQ:META) 
Via Benzinga
Undervalued Icons: 3 Household Names Trading at Steep Discounts
Three of Wall Street's undervalued stocks could provide a unique blend of stability and long-term growth potential. 
Via InvestorPlace
Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week
Corporate profit growth rose in Q3 2023 and is expected to continue in Q1. 
Via Benzinga
FDA Mandates "Boxed Warning" For Bristol Myers, Johnson & Johnson CAR-T-Based Blood Cancer Therapies
Following an investigation announced in November last year, the FDA said on Thursday that it would now require boxed warnings—the highest safety-rel 
Via Benzinga
Exposures Product Safety
Better Growth Play: Merck or The Vanguard Growth Index Fund?
Merck's shares are trading in bargain territory. Are they a better growth play than this popular Vanguard fund? 
Via The Motley Fool
Should You Buy the 3 Highest-Paying Dividend Stocks in the Nasdaq?
Dividend stocks can be a smart way to ride out market volatility. 
Via The Motley Fool
Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Quarter
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
3 Stocks at 52-Week Lows Poised for a Powerful Rebound
Starbucks, Gilead, and Vale are three stocks at 52-week lows that show signs of recovery potential and long-term growth prospects. 
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Starbucks, Gilead And Ambev Are At 52-Week Lows: Should You Buy The Dip?
Capital market investors often look for entry points, hidden gems, and value bets. Quality stocks trading at or around their 52-week low levels offer one such opportunity window. 
Via Benzinga
3 No-Brainer Dividend Stocks to Buy in April
Income investors will find a lot to like about these stocks. 
Via The Motley Fool
Got $5,000? These 3 High-Yielding Dividend Stocks Are Trading Near Their 52-Week Lows
All of these stocks pay generous dividends that income investors will appreciate. 
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
5 Healthcare Stocks to Buy for 2024
Healthcare stocks have been some of the top performers in 2024, and thanks to the potential of AI, these names will just keep heating up. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Galapagos Downgraded, Pharma Firm Faces Uphill Battle With Slow Pipeline Progress: Analyst
BofA Securities downgrades Galapagos to underperform due to limited near-term catalysts and competitive challenges in crowded markets. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
30 31 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.